NewsBenzingaBioVie公布ADDRESS-LC试验中Bezisterim治疗长新冠的新生物标志物数据;分析表明,单一疗效终点可能不足以全面捕捉长新冠生物学多样性背景下治疗干预所带来的具有临床意义的反应 BioVie公布ADDRESS-LC试验中Bezisterim治疗长新冠的新生物标志物数据;分析表明,单一疗效终点可能不足以全面捕捉长新冠生物学多样性背景下治疗干预所带来的具有临床意义的反应 Benzinga 2026.11.09 13:05 (GMT+0) Open on Benzinga Other news Motorola Solutions Hikes Quarterly Dividend From $1.21 To $1.34 Per Share These 9 Congress Members Could Have Increased Interest in Nvidia’s Q3 Earnings as 2026 Shareholders $100 Invested In Cigna Group 20 Years Ago Would Be Worth This Much Today Needham Maintains Buy on FuboTV, Lowers Price Target to $10 BTIG Reiterates Buy on Amer Sports, Maintains $42 Price Target Ahead of Palo Alto Networks Earnings, Here's What Barchart Data Says Comes Next for PANW Stock